MCID: ACN001
MIFTS: 44

Acinar Cell Carcinoma

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Acinar Cell Carcinoma

MalaCards integrated aliases for Acinar Cell Carcinoma:

Name: Acinar Cell Carcinoma 12 15 17 70
Acinic Cell Carcinoma 12 20
Carcinoma, Acinar Cell 44
Carcinoma Acinar Cell 54
Acinic Cell Tumor 20
Acinar Cell Tumor 70

Classifications:



External Ids:

Disease Ontology 12 DOID:3025
MeSH 44 D018267
NCIt 50 C3768
SNOMED-CT 67 45410002
UMLS 70 C0206685 C0334390

Summaries for Acinar Cell Carcinoma

Disease Ontology : 12 A carcinoma that has material basis in abnormally proliferating cells, derives from spindle cells and/or derives from giant cells.

MalaCards based summary : Acinar Cell Carcinoma, also known as acinic cell carcinoma, is related to pancreatic acinar cell adenocarcinoma and pancreatic ductal adenocarcinoma. An important gene associated with Acinar Cell Carcinoma is CHGA (Chromogranin A), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Fluorouracil and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include pancreas, salivary gland and breast, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Acinar Cell Carcinoma

Diseases related to Acinar Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 388)
# Related Disease Score Top Affiliating Genes
1 pancreatic acinar cell adenocarcinoma 32.1 SERPINA3 REG1A CPA1 CHGA BCL10 AFP
2 pancreatic ductal adenocarcinoma 30.9 TP53 SMAD4 CTNNB1 BRCA2
3 pancreatic ductal carcinoma 30.7 TP53 SMAD4 KRT7
4 pancreatic adenocarcinoma 30.7 TP53 SMAD4 CTNNB1 BRCA2
5 mucoepidermoid carcinoma 30.7 TP53 SERPINA3 KRT7 CTNNB1 CHGA
6 mammary analogue secretory carcinoma 30.5 TP53 NTRK3 ETV6 CTNNB1
7 neuroendocrine carcinoma 30.4 KRT7 GAST CHGA
8 pancreatitis 30.3 SMAD4 SERPINA3 SERPINA1 REG1A CPA1
9 cowden syndrome 1 30.3 TP53 STK11 SMAD4 BRCA2
10 pancreatoblastoma 30.2 SERPINA3 SERPINA1 CTNNB1 CHGA AFP
11 glucagonoma 30.2 GAST CHGA
12 cystadenocarcinoma 30.2 TP53 SERPINA3 KRT7
13 carcinosarcoma 30.2 TP53 KRT7 CTNNB1
14 adenoid cystic carcinoma 30.2 TP53 SERPINA3 NTRK3 KRT7 CTNNB1
15 lynch syndrome 30.1 TP53 STK11 SMAD4 CTNNB1 BRCA2
16 islet cell tumor 30.1 SERPINA3 IGF2 GAST CHGA BRCA2
17 microinvasive gastric cancer 30.1 TP53 GAST AFP
18 pleomorphic adenoma 30.1 TP53 KRT7 CTNNB1
19 tubular adenocarcinoma 30.1 KRT7 CTNNB1 CHGA AFP
20 intrahepatic cholangiocarcinoma 30.0 TP53 SMAD4 KRT7 CTNNB1 AFP
21 cholangiocarcinoma 30.0 TP53 SMAD4 KRT7 CTNNB1 AFP
22 cystadenoma 30.0 SERPINA3 KRT7 CHGA AFP
23 cowden syndrome 30.0 TP53 STK11 SMAD4 CTNNB1 BRCA2
24 in situ carcinoma 30.0 TP53 SERPINA3 CTNNB1 BRCA2
25 pleomorphic adenoma carcinoma 29.9 TP53 NTRK3
26 adenoma 29.9 TP53 SMAD4 KRT7 CTNNB1 CHGA
27 hemangioma 29.8 TP53 KRT7 IGF2 GAST CTNNB1 CHGA
28 breast secretory carcinoma 29.8 SERPINA3 NTRK3 ETV6
29 adenocarcinoma 29.5 TP53 STK11 SMAD4 NTRK3 KRT7 CTNNB1
30 liver cirrhosis 29.5 TP53 SERPINA3 SERPINA1 CTNNB1 AFP
31 salivary gland carcinoma 29.3 TP53 SERPINA3 NTRK3 KRT7 ETV6
32 constipation 29.2 NTRK3 GAST CHGA ANO1
33 gastrointestinal stromal tumor 29.2 TP53 NTRK3 IGF2 CHGA ANO1
34 endometrial cancer 29.2 TP53 STK11 SMAD4 SERPINA3 KRT7 IGF2
35 pancreatic cancer 29.0 TP53 STK11 SMAD4 SERPINA3 REG1A KRT7
36 acinar cell carcinoma of pancreas 11.7
37 rare tumor 10.7
38 panniculitis 10.6
39 papillary carcinoma 10.5
40 basaloid lung carcinoma 10.4 TP53 BRCA2
41 obstructive jaundice 10.4
42 familial colorectal cancer type x 10.4 SMAD4 BRCA2
43 pancreatic serous cystadenoma 10.4 STK11 CHGA
44 auditory system benign neoplasm 10.4 KRT7 CHGA
45 pancreatic serous cystadenocarcinoma 10.4 KRT7 CHGA
46 pancreatic foamy gland adenocarcinoma 10.4 TP53 KRT7
47 pax6-related aniridia 10.4 IGF2 BRCA2
48 laryngeal neuroendocrine tumor 10.4 TP53 CHGA
49 female urethral cancer 10.4 KRT7 CHGA
50 gallbladder small cell carcinoma 10.4 KRT7 CHGA

Graphical network of the top 20 diseases related to Acinar Cell Carcinoma:



Diseases related to Acinar Cell Carcinoma

Symptoms & Phenotypes for Acinar Cell Carcinoma

GenomeRNAi Phenotypes related to Acinar Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.98 SMAD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-109 9.98 IGF2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.98 SMAD4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.98 IGF2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-134 9.98 IGF2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.98 KRT7
7 Increased shRNA abundance (Z-score > 2) GR00366-A-148 9.98 IGF2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.98 IGF2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.98 KRT7
10 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.98 IGF2 SMAD4
11 Increased shRNA abundance (Z-score > 2) GR00366-A-212 9.98 SMAD4
12 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.98 SMAD4
13 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.98 SMAD4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.98 CTNNB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.98 IGF2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-68 9.98 KRT7
17 Increased shRNA abundance (Z-score > 2) GR00366-A-72 9.98 KRT7
18 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.98 KRT7
19 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.98 IGF2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.98 KRT7
21 Reduced mammosphere formation GR00396-S 9.23 AFP CHGA ETV6 IGF2 KRT7 PLA2G1B

MGI Mouse Phenotypes related to Acinar Cell Carcinoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 AFP ANO1 BRCA2 CHGA CPA1 CTNNB1
2 endocrine/exocrine gland MP:0005379 10.29 AFP BCL10 BRCA2 CHGA CPA1 CTNNB1
3 digestive/alimentary MP:0005381 10.24 ANO1 BRCA2 CPA1 CTNNB1 ETV6 GAST
4 mortality/aging MP:0010768 10.21 AFP ANO1 BCL10 BRCA2 CHGA CTNNB1
5 integument MP:0010771 10.09 ANO1 BRCA2 CTNNB1 ETV6 IGF2 SERPINA3
6 liver/biliary system MP:0005370 10.01 AFP CTNNB1 ETV6 IGF2 PLA2G1B SMAD4
7 neoplasm MP:0002006 9.92 AFP BRCA2 CTNNB1 ETV6 GAST SMAD4
8 normal MP:0002873 9.81 BRCA2 CPA1 CTNNB1 ETV6 NTRK3 SERPINA1
9 no phenotypic analysis MP:0003012 9.8 CHGA CTNNB1 ETV6 IGF2 NTRK3 STK11
10 renal/urinary system MP:0005367 9.56 ANO1 CHGA CTNNB1 IGF2 KRT7 SMAD4
11 reproductive system MP:0005389 9.32 AFP BRCA2 CHGA CTNNB1 IGF2 NTRK3

Drugs & Therapeutics for Acinar Cell Carcinoma

Drugs for Acinar Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 3 51-21-8 3385
2
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
3
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
4
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
5 Protein Kinase Inhibitors Phase 3
6 Immunosuppressive Agents Phase 2, Phase 3
7 Immunologic Factors Phase 2, Phase 3
8 Antiviral Agents Phase 2, Phase 3
9 Antimetabolites Phase 2, Phase 3
10 Anti-Infective Agents Phase 2, Phase 3
11 Phosphoramidic acid Phase 2, Phase 3
12
Pancrelipase Approved, Investigational Phase 2 53608-75-6
13
Metformin Approved Phase 2 657-24-9 14219 4091
14
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
15
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
16
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
17
Ipilimumab Approved Phase 2 477202-00-9
18
nivolumab Approved Phase 2 946414-94-4
19
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
20
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
21
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
22
leucovorin Approved Phase 2 58-05-9 6006
23
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
24
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
25
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
26
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
28 Bryostatin 1 Investigational Phase 2 83314-01-6
29 pancreatin Phase 2
30 Hypoglycemic Agents Phase 2
31 Angiogenesis Inhibitors Phase 2
32 Adjuvants, Immunologic Phase 2
33 Immunoglobulins Phase 2
34 Antibodies, Monoclonal Phase 2
35 Antibodies Phase 2
36 Antimitotic Agents Phase 1, Phase 2
37 Albumin-Bound Paclitaxel Phase 1, Phase 2
38 Tubulin Modulators Phase 1, Phase 2
39 Micronutrients Phase 2
40 Antidotes Phase 2
41 Trace Elements Phase 2
42 Nutrients Phase 2
43 Vitamin B9 Phase 2
44 Vitamin B Complex Phase 2
45 Folate Phase 2
46 Hormones Phase 2
47 Protective Agents Phase 2
48 Vitamins Phase 2
49 Calcium, Dietary Phase 2
50 topoisomerase I inhibitors Phase 2

Interventional clinical trials:

(show all 29)
# Name Status NCT ID Phase Drugs
1 A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma Active, not recruiting NCT01013649 Phase 3 Capecitabine;Chemotherapy;Erlotinib Hydrochloride;Fluorouracil;Gemcitabine Hydrochloride
2 A Phase III, Open Label, Multicentre Randomised Clinical Study Comparing Acelarin (NUC-1031) With Gemcitabine in Patients With Metastatic Pancreatic Carcinoma Suspended NCT03610100 Phase 2, Phase 3 Acelarin;Gemcitabine
3 A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer Completed NCT01280058 Phase 2 Carboplatin;Paclitaxel
4 Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients With Metastatic Pancreatic Cancer After Prior Chemotherapy Completed NCT01658943 Phase 2 Akt Inhibitor MK2206;Fluorouracil;Oxaliplatin;Selumetinib
5 A Phase II Study of Metformin Plus Modified FOLFOX 6 in Patients With Metastatic Pancreatic Cancer Completed NCT01666730 Phase 2 metformin hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
6 A Multicenter, Open-Label, Randomized, Phase II Trial of Adjuvant Dasatinib Plus Gemcitabine Versus Single-Agent Gemcitabine in Patients With Resected Pancreatic Adenocarcinoma Completed NCT01234935 Phase 2 dasatinib;gemcitabine hydrochloride
7 A Phase II Study of Sunitinib Malate (SU11248, NSC #736511, IND #74,019) in Patients With Previously Treated Pancreatic Adenocarcinoma With Measurable Metastatic Disease Following Progression on Front-Line Gemcitabine-Based Therapy Completed NCT00397787 Phase 2 sunitinib malate
8 A Phase II Study Of Triapine For Advanced Adenocarcinoma Of The Pancreas Completed NCT00085371 Phase 2 triapine
9 A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands Completed NCT00095563 Phase 2 lapatinib ditosylate
10 A Phase II Study of Sequential Paclitaxel and Bryostatin-1 for Patients With Advanced Pancreatic Cancer Completed NCT00031694 Phase 2 paclitaxel;bryostatin 1
11 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
12 Phase Ib Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and Nab-Paclitaxel and Phase II Study of Gemcitabine and Selinexor in Patients With Metastatic Pancreatic Cancer Recruiting NCT02178436 Phase 1, Phase 2 gemcitabine hydrochloride;Selinexor;Nab paclitaxel
13 Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer Recruiting NCT02047474 Phase 2 oxaliplatin;leucovorin calcium;irinotecan hydrochloride;fluorouracil
14 A Phase II Study of Bortezomib in Combination With Carboplatin in Patients With Metastatic Pancreatic Cancer Terminated NCT00416793 Phase 2 bortezomib;carboplatin
15 Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland Carcinoma Terminated NCT00126607 Phase 2
16 Phase I Trial of The Combination of Vismodegib and Sirolimus Completed NCT01537107 Phase 1 vismodegib;sirolimus
17 A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies Completed NCT01643499 Phase 1 oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil
18 A Phase I/II Study of Sorafenib and Everolimus in Patients With Advanced Solid Tumors and Gemcitabine-Refractory Metastatic Pancreatic Cancer Completed NCT00981162 Phase 1 sorafenib tosylate;everolimus
19 A Pilot Study: Open-Label Clinical Trial of CPI-613 in Patients With Metastatic Pancreatic Adenocarcinoma and Poor Performance Status Completed NCT01839981 Phase 1 6,8-bis(benzylthio)octanoic acid
20 Open-label, Single-center, Non-randomized, Phase I, Dose-ranging Study of Endoscopic Ultrasound (EUS) Guided Photodynamic Therapy (PDT) With Photofrin® in Locally Advanced Pancreatic Cancer Completed NCT01770132 Phase 1 porfimer sodium;gemcitabine hydrochloride
21 Immunotherapy for Unresectable Pancreas Cancer: A Phase 1 Study of Intratumoral Recombinant Fowlpox PANVAC (PANVAC-F) Plus Subcutaneous Recombinant Vaccinia PANVAC (PANVAC-V), PANVAC-F and Recombinant Granulocyte-Macrophage Colony Stimulating Factor (rH-GM-CSF) Active, not recruiting NCT00669734 Phase 1
22 Phase I Trial of the Combination of Vismodegib GDC-0449 and Erlotinib +/- Gemcitabine Active, not recruiting NCT00878163 Phase 1 Erlotinib Hydrochloride;Gemcitabine Hydrochloride;Vismodegib
23 Phase I Study of the Combination of MLN8237 and Gemcitabine in Advanced Solid Tumors With Emphasis on Pancreatic Cancer Active, not recruiting NCT01924260 Phase 1 alisertib;gemcitabine
24 A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status Active, not recruiting NCT01835041 Phase 1 6,8-bis(benzylthio)octanoic acid;oxaliplatin;leucovorin calcium;irinotecan hydrochloride;fluorouracil
25 RT-054: A Phase I Study of Neoadjuvant Hypofractionated Chemoradiation Plus Radiosurgical Boost for Patients With Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer Terminated NCT01739439 Phase 1 gemcitabine hydrochloride
26 A First Time in Human Phase I Imaging Study of iRGD in Patients With Advanced Breast and Pancreas Cancer Withdrawn NCT01741597 Phase 1
27 A Pilot Trial of Stereotactic Body Radiation Therapy and Metformin for Borderline-Resectable and Locally-Advanced Pancreatic Adenocarcinomas Completed NCT02153450 Early Phase 1 metformin hydrochloride
28 Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients With Borderline Resectable Pancreatic Adenocarcinoma: An Intergroup Single-Arm Pilot Study Completed NCT01821612 Early Phase 1 oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;gemcitabine
29 The WASH (Water or Saline at High Volumes) Trial: A Randomized Trial to Assess the Survival Impact of Extensive Peritoneal Lavage Using Distilled WAter or Saline at High Volumes After Pancreatic Resection for Pancreatic Ductal Adenocarcinoma Recruiting NCT02757859

Search NIH Clinical Center for Acinar Cell Carcinoma

Cochrane evidence based reviews: carcinoma, acinar cell

Genetic Tests for Acinar Cell Carcinoma

Anatomical Context for Acinar Cell Carcinoma

MalaCards organs/tissues related to Acinar Cell Carcinoma:

40
Pancreas, Salivary Gland, Breast, Thyroid, Liver, Lung, Appendix

Publications for Acinar Cell Carcinoma

Articles related to Acinar Cell Carcinoma:

(show top 50) (show all 1264)
# Title Authors PMID Year
1
Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas. 61 54
19720778 2009
2
Alpha-fetoprotein-positive carcinoma of the pancreas: a case report. 61 54
16033080 2005
3
Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. 54 61
11891193 2002
4
Pancreatic acinar cell carcinoma with endocrine differentiation: immunohistochemical and ultrastructural analyses. 54 61
11501836 2001
5
Alpha-fetoprotein production by pancreatic tumors exhibiting acinar cell differentiation: study of five cases, one arising in a mediastinal teratoma. 54 61
10987254 2000
6
Alpha fetoprotein-producing acinar cell carcinoma of the pancreas showing multiple lines of differentiation. 61 54
7541276 1995
7
Expression of human regenerating gene mRNA and its product in normal and neoplastic human pancreas. 61 54
1525759 1992
8
Significance of Nodal Metastasis in Parotid Gland Acinar Cell Carcinoma. 61
32770798 2021
9
Distant metastasis from oral cavity-correlation between histopathology results and primary site. 61
32468449 2021
10
Usefulness of immunohistochemistry to distinguish between secretory carcinoma and acinic cell carcinoma in the salivary gland. 61
32488412 2021
11
Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma. 61
33169486 2021
12
Acinar Cell Carcinoma with Morphological Change in One Month. 61
33746172 2021
13
Pancreatic Acinar Cell Carcinoma with Concomitant Bullous Pemphigoid. 61
33757939 2021
14
Heterotopic acinic cell carcinoma and its clinical implications. 61
33177745 2021
15
Use of 68Ga-FAPI PET/CT for Evaluation of Peritoneal Carcinomatosis Before and After Cytoreductive Surgery. 61
33782310 2021
16
Secretory Carcinoma of the Oral Cavity: A Retrospective Case Series with Review of Literature. 61
33660147 2021
17
Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AciCC) of the Salivary Glands. 61
33669038 2021
18
Differential diagnosis between acinic cell carcinoma and pleomorphic adenoma using the quantitative parameters of contrast-enhanced ultrasound. 61
33660803 2021
19
Comprehensive Analysis of Clinicopathologic Factors Predictive of an Unfavorable Prognosis in Patients With Acinic Cell Carcinoma of the Parotid Gland. 61
32392906 2021
20
Evaluation of NR4A3 immunohistochemistry (IHC) and fluorescence in situ hybridization and comparison with DOG1 IHC for FNA diagnosis of acinic cell carcinoma. 61
32809265 2021
21
Acinic cell carcinoma of the salivary gland associated with lymphoid-rich stroma. A diagnostic dilemma on cytology: Study of two cases. 61
32761994 2021
22
A correlation study of mismatch repair immunohistochemical protein expression of pancreatic solid tumors in cytology cell blocks and matching surgical specimens. 61
33615705 2021
23
The cytologic and immunohistochemical findings of pancreatic mixed acinar-endocrine carcinoma. 61
33128511 2021
24
Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: A single institutional comparison to pancreatic ductal adenocarcinoma. 61
33611029 2021
25
Title: pancreatic-type mixed acinar neuroendocrine carcinoma of the stomach: a case report and review of the literature. 61
33531019 2021
26
Clinical study of salivary gland malignant tumor with skull base metastasis. 61
33641541 2021
27
Salivary gland tumours in Iceland 1986-2015: a nationwide epidemiological analysis over a 30-year time period. 61
33064861 2021
28
Fatal case of pancreatic panniculitis caused by occult neuroendocrine tumor in the corresponding organ: A case report and review of the published work. 61
33073392 2021
29
Intensity-modulated proton therapy (IMPT) versus intensity-modulated radiation therapy (IMRT) for the treatment of head and neck cancer: A dosimetric comparison. 61
33648823 2021
30
Histopathological evaluation of needle tract seeding caused by EUS-fine-needle biopsy based on resected specimens from patients with solid pancreatic masses: An analysis of 73 consecutive cases. 61
33586689 2021
31
Secretory carcinoma of salivary glands at the National Cancer Institute: A 20-year retrospective clinical, pathological, immunohistochemical and molecular study. 61
33573874 2021
32
Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature. 61
33406492 2021
33
Multicenter Retrospective Analysis of Chemotherapy for Advanced Pancreatic Acinar Cell Carcinoma: Potential Efficacy of Platinum- and Irinotecan-Containing Regimens. 61
33370026 2021
34
Ectopic ACTH Production Caused by Metastatic Parotid Gland Acinic Cell Carcinoma. 61
33718604 2021
35
Clinicopathological analysis of oral and maxillofacial acinic cell carcinoma: A systematic review. 61
33455041 2021
36
Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands. 61
33401730 2021
37
Soft tissue metastasis revealing a case of acinar cell carcinoma of unknown primary origin. 61
33363815 2020
38
Rare case of acinar cell carcinoma with multiple lesions in the pancreas. 61
33319067 2020
39
Efficacy of chemotherapy combined with toripalimab in PD-L1-positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report. 61
33345750 2020
40
[Successful Surgical Resection of Expansive-Growth Acinar Cell Carcinoma-A Case Report]. 61
33468914 2020
41
[Resection of the Acinar Cell Carcinoma of the Pancreas with Lymph Node Recurrence along the Lesser Curvature of the Stomach-A Case Report]. 61
33468857 2020
42
The Decline of Salivary Adenocarcinoma Not Otherwise Specified as a Tumor Entity: Reclassification Using Contemporary Immunohistochemical Profiling and Diagnostic Criteria. 61
33284193 2020
43
[A Case of Primary Acinic Cell Carcinoma of the Breast]. 61
33468761 2020
44
Fine needle aspiration of salivary gland carcinomas with high-grade transformation: A multi-institutional study of 22 cases and review of the literature. 61
33211402 2020
45
[Expression of NR4A3/NOR-1 in acinic cell carcinoma of the salivary gland]. 61
33152819 2020
46
Acinar cell carcinoma of the pancreas: a clinicopathologic and cytomorphologic review. 61
32461075 2020
47
Pancreatic panniculitis and elevated serum lipase in metastasized acinar cell carcinoma of the pancreas: A case report and review of literature. 61
33269263 2020
48
Acinic cell carcinoma of the salivary gland in the adult and paediatric population: a survival analysis. 61
33205582 2020
49
A Very Rare Complication of Vocal Fold Augmentation With Calcium Hydroxylapatite: Neck Abscess. 61
33153855 2020
50
Clinicopathologic Features and Survival Trends for Acinic Cell Carcinoma of the Major Salivary Glands: A Surveillance, Epidemiology, and End Results Population Analysis. 61
33117462 2020

Variations for Acinar Cell Carcinoma

Copy number variations for Acinar Cell Carcinoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 107120 19 1205798 1228434 Amplification STK11 Acinar cell carcinoma
2 118120 17 7571720 7590868 Mutation TP53 Acinar cell carcinoma

Expression for Acinar Cell Carcinoma

Search GEO for disease gene expression data for Acinar Cell Carcinoma.

Pathways for Acinar Cell Carcinoma

Pathways related to Acinar Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.38 TP53 SMAD4 IGF2 CTNNB1 BRCA2
2
Show member pathways
12.22 TP53 SMAD4 IGF2 CTNNB1 BRCA2
3 11.21 TP53 STK11 SMAD4 CTNNB1 BRCA2
4 10.76 TP53 STK11 SMAD4

GO Terms for Acinar Cell Carcinoma

Cellular components related to Acinar Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 SERPINA3 SERPINA1 REG1A PLA2G1B IGF2 GAST
2 extracellular space GO:0005615 9.28 SERPINA3 SERPINA1 REG1A PLA2G1B IGF2 GAST
3 platelet alpha granule lumen GO:0031093 9.13 SERPINA3 SERPINA1 IGF2

Biological processes related to Acinar Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 in utero embryonic development GO:0001701 9.26 TP53 SMAD4 IGF2 CTNNB1
2 negative regulation of cell proliferation GO:0008285 9.02 TP53 STK11 SMAD4 REG1A CTNNB1

Molecular functions related to Acinar Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.43 TP53 REG1A CTNNB1
2 p53 binding GO:0002039 9.33 TP53 STK11 NTRK3
3 RNA polymerase II transcription factor binding GO:0001085 9.13 TP53 SMAD4 CTNNB1
4 protease binding GO:0002020 8.92 TP53 SERPINA1 BRCA2 BCL10

Sources for Acinar Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....